Sales & Marketing News | pharmaphorum

News

First drug therapy for frostbite has been cleared by FDA

People at risk of losing a finger or toe to frostbite now have the first FDA-approved treatment that could prevent a life-changing amputation.

News

Onivyde gets ‘practice-changing’ FDA OK in pancreatic cancer

Ipsen has won FDA approval for first-line use of its pancreatic cancer therapy Onivyde, saying it is now part of a potential new “standard-of-care” for patients.

News

Biogen’s Skyclarys is first EU drug for Friedreich’s ataxia

After getting a green light from the European Commission, Biogen’s Skyclarys is the first approved medicine for the inherited neurological disease Friedreich’s ataxia (FA)

News

White House wins in first Medicare negotiation legal ruling

A judge in a federal court in Texas has thrown out a lawsuit brought by the pharma industry challenging legislation introduced by the Biden administration that allows Medi

News

FDA changes its mind and approves Takeda’s Eohilia

In its second attempt, Takeda has secured FDA approval for Eohilia, which becomes the first and only oral therapy in the US for eosinophilic oesophagitis (EoE).

News

Gilead to buy liver disease specialist CymaBay for $4.3bn

Gilead Sciences has beefed up its pipeline with an agreement to buy CymaBay Therapeutics and its seladelpar drug for rare liver disease primary biliary cholangitis (PBC),

First drug therapy for frostbite has been cleared by FDA

Onivyde gets ‘practice-changing’ FDA OK in pancreatic cancer

Biogen’s Skyclarys is first EU drug for Friedreich’s ataxia

White House wins in first Medicare negotiation legal ruling

FDA changes its mind and approves Takeda’s Eohilia

Gilead to buy liver disease specialist CymaBay for $4.3bn

HHS doubles down on controversial peptides plan

Discover a new era of healthcare panel engagement: Grounded ...

News

Editor's Picks